

## Preliminary communication

# Expedient syntheses of inososes from carbohydrates: conformational and stereoelectronic aspects of the Ferrier reaction

Antonio S. Machado <sup>a</sup>, Didier Dubreuil <sup>b</sup>, Jeannine Cleophax <sup>b</sup>,  
Stephane D. Gero <sup>b</sup> and Noel F. Thomas <sup>c</sup>

<sup>a</sup> Nucleo Multifuncional de Pesquisas Quimicas, Universidade Federal de Juiz de Fora, 36.100 - Juiz de Fora, Minas Gerais (Brazil)

<sup>b</sup> Institut de Chimie des Substances Naturelles, C.N.R.S., 91198 Gif-sur-Yvette (France)

<sup>c</sup> School of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY (United Kingdom)


(Received January 25th, 1992; accepted May 16th, 1992)

The conversion of 6-deoxyhex-5-enopyranosides (e.g., **1**, Table I and Scheme 1) into cyclohexanones [inosose derivatives, e.g., **2**, Table I and Scheme 1] by reaction with  $\text{HgCl}_2$  (1.1 equiv) in aqueous dioxane or aqueous acetone was first disclosed by Ferrier<sup>1</sup>. Although the importance of this reaction has been recognised<sup>2–4</sup>, its scope has not been examined fully. Machado et al.<sup>5</sup> recognised the relationship between the conformation of the starting carbohydrate and the stereochemistry of the Ferrier product, and we now report a more detailed mechanistic study.

TABLE I  
Ferrier reactions

Olefin	Product	Conditions <sup>a</sup>	Ref.	Yield (%)
<b>1</b>	<b>2</b>	1.1 equiv $\text{HgCl}_2$ –A	1	83
<b>3</b>	<b>4</b>	1 equiv $\text{HgCl}_2$ –A <sup>b</sup>	2, 12	84
<b>5</b>	<b>6</b>	catalytic $\text{Hg}(\text{SO}_4)$ –B	5	80
<b>7</b>	<b>8</b>	$\text{Hg}(\text{CF}_3\text{CO}_2)_2$ –A	8	75
<b>9</b>	<b>10</b>	catalytic $\text{HgSO}_4$ –B <sup>c</sup>		85
<b>11</b>	<b>12</b>	catalytic $\text{HgSO}_4$ –B	9	quantitative

<sup>a</sup> A, 1:2  $\text{H}_2\text{O}$ –dioxane or 1:2  $\text{H}_2\text{O}$ –acetone; B, 1:2  $\text{H}_2\text{O}$  (0.5 mmol  $\text{H}_2\text{SO}_4$ )–dioxane. <sup>b</sup> With 1.1 equiv of  $\text{HgCl}_2$ , **4** and its epimer were isolated in the ratio 2:1<sup>12</sup>. <sup>c</sup> With 1.1 equiv of  $\text{HgCl}_2$ , elimination of the azido group occurs<sup>9</sup>.




Scheme 1.

The hex-5-enopyranosides (**1**, **3**, **5**, **7**, **9**, and **11**; Table I and Scheme 1) studied were prepared by well established procedures<sup>6–10</sup>. Each hexenopyranoside was dissolved in methanol and the conformation (in the absence of HgCl<sub>2</sub>) was determined by 300-<sup>1</sup>H NMR spectroscopy. With the exception of **7** and **9**, the data agreed with those in the literature and the conformations are shown in Scheme 1. The structures and conformations of the products (**2**, **4**, **6**, **8**, **10**, and **12**, respectively; Scheme 1) were also determined by <sup>1</sup>H NMR spectroscopy.

Laszlo et al.<sup>6</sup>, in a study of the mercury salt-mediated ring-transformation of methyl hex-5-enopyranoside derivatives, noted that, in the cyclohexanone products, the newly generated HO-5 and the 3-substituent were *trans* (C-1 in the hex-5-enopyranoside becomes C-5 in the cyclohexanone). The same outcome was found for the transformations shown in Table I. The high stereoselectivity associated with this reaction has been attributed<sup>6</sup> to a highly strained, boat transition state in which C-6 is connected to the 3-substituent via the mercury cation. An alternative, more precise explanation involves the sequence **1** → **13** → **14** → **15** → **16** → **2** (Scheme 2) and a six-membered chair transition state **16** which accounts for the stereochemistry at C-5 of the major product, and the sequence **15** → **17** → **18** → **19** which accounts for the stereochemistry of the minor isomer.

The results in Table I indicate that the methyl hex-5-enopyranoside derivatives **1**, **3**, and **5**, in the <sup>4</sup>C<sub>1</sub> conformation with MeO-1 axial, each gave a hydroxycyclohexanone derivative (**2**, **4**, and **6**, respectively) with HO-5 directed downward. By contrast, **7**, **9**, and **11**, each in the <sup>1</sup>C<sub>4</sub> conformation, gave a hydroxycyclohexanone derivative with HO-5 directed upward. The stereoelectronic explanation involves the addition of mercury to the olefinic bond of, for example, **1** to give **13** which is



Scheme 2.

trapped by water to give 14. Indeed, stable isolable products analogous to 14, obtained by trapping of the carbonium ion (or the mercurinium ion precursor) with dry methanol, have been reported by Ferrier and Prasit<sup>11</sup>. The formation of 14 is followed by opening of the pyranoside ring with concomitant loss of MeO-1 to

yield the ketoaldehyde intermediates **15** and **17**. The transition state **16** derived from **15** has a chair conformation and is favoured over the twist form **18**. The equilibrium between **15** and **17** would be expected to be well to the left, resulting in the preponderant formation of **2** with only a minor proportion of the C-5 epimer **19**.

The mechanism noted above for the reaction of **1** (and also **3** and **5**) in the  ${}^4C_1$  conformation also applies to **7**, **9**, and **11**, which are in the  ${}^1C_4$  conformation. The reason for the predominance of the stereochemistry of the main product from, for example, **7** is due to the transition state **20** which yields **8**.

The presence of an axial substituent at C-3 should destabilise **16** by a 1,3-diaxial interaction, shift the equilibrium towards **15** and **17**, and result in an increase in the proportion of the minor isomer. A more detailed account of these mechanistic interpretations will be published elsewhere.

## REFERENCES

- 1 R.J. Ferrier, *J. Chem. Soc., Perkin Trans. 1*, (1979) 1455–1458.
- 2 N. Sakairi and H. Kuzuhara, *Tetrahedron Lett.*, (1982) 5327–5330.
- 3 E. Truscheit, W. Frommer, B. Junge, L. Müller, D.D. Schmidt, and W. Wingender, *Angew. Chem. Int. Ed. Engl.*, 20 (1981) 744–761.
- 4 S. Ogawa, T. Nose, T. Ogawa, T. Toyokuni, Y. Iwasawa, and T. Suami, *J. Chem. Soc., Perkin Trans. 1*, (1985) 2369–2374; S. Ogawa, Y. Miyamoto, and T. Nose, *ibid.*, (1988) 2675–2680; Y. Kameda, N. Asano, T. Yamaguchi, K. Matsui, S. Horii, and H. Fukase, *J. Antibiot.*, 39 (1986) 1491–1494; U. Brodbeck, in *Enzyme Inhibitors*, Verlag Chemie, 1980, pp 109–153.
- 5 A.S. Machado, A. Olesker, and G. Lukacs, *Carbohydr. Res.*, 135 (1985) 231–239.
- 6 P. Laszlo, I.F. Pelyvas, F. Sztaricskai, L. Szilagyi, and A. Somogyi, *Carbohydr. Res.*, 175 (1988) 227–239.
- 7 D.H.R. Barton, S.D. Gero, S. Augy, and B. Quicklet-Sire, *J. Chem. Soc., Chem. Commun.*, (1986) 1399–1401.
- 8 F. Chretien and Y. Chapleur, *J. Chem. Soc., Chem. Commun.*, (1984) 1268–1269.
- 9 A.S. Machado, A. Olesker, S. Castillon, and G. Lukacs, *J. Chem. Soc., Chem. Commun.*, (1985) 330–332.
- 10 D. Horton and W. Weckerle, *Carbohydr. Res.*, 44 (1975) 227–240.
- 11 R.J. Ferrier and P. Prasit, *Carbohydr. Res.*, 82 (1980) 263–272.
- 12 D. Semeria, M. Philippe, J.M. Delaumeny, A.M. Sepulchre, and S.D. Gero, *Synthesis*, (1983) 710–713.